Applied Biosystems' Singapore Facility Achieves ISO 13485 Certification

Milestone Part of Company Strategy to Serve Customers in Applied and Validated Markets

Applied Biosystems (NYSE:ABI) today announced that its Singapore facility has received an important ISO quality certification, enhancing the company's ability to serve its customers in applied and validated markets. The British Standards Institution Americas, Inc. has awarded the company with an ISO 13485:2003 certification for in-vitro diagnostic medical devices. This is a stringent, globally recognized management system standard that enables CE Marking to the In-Vitro Diagnostics Directive 98/79/EC of products for sale within the European Community. The CE Mark certifies that a product has met European Union health, safety, and environmental requirements, which are intended to ensure consumer safety.

Applied Biosystems, which currently markets instrument systems for research use only, obtained the certification to support its increased focus on commercial applications of molecular technologies. These include quality and safety testing, human identification, food and environmental testing, forensics, pharmaceutical manufacturing and clinical testing among others. The company's strategy is to continue to serve its customers by meeting their requirements to translate and implement scientific discoveries into applied, clinical and validated settings.

"This is an important milestone in Applied Biosystems' strategy to evolve based upon the changing needs of our customers," said Mark Stevenson, president and chief operating officer for Applied Biosystems Group. "One of our goals is to implement and execute improvements in our quality management systems to support our initiatives in applied and validated markets. We are committed to meeting the requirements of our customers as they translate and implement scientific discoveries into the clinical setting."

Applied Biosystems is a global leader in the development and commercialization of instrument-based systems, consumables, software and services for the life-science market. The company is also a market leader in systems and reagents for DNA sequencing, real-time PCR and mass spectrometry.

As part of its ongoing quality initiative in its manufacturing operations, the company's environmental, health, and safety management system in Singapore has been successfully audited by BSI and has achieved certification to ISO 14001:2004 Environmental Management System, and OHSAS 18001:2007 Occupational Health & Safety Management System standards. These certifications demonstrate a commitment to risk assessment of the company's products and activities, monitoring of environmental, health, and safety regulations and their associated controls, and achieving continual improvement in manufacturing processes.

About Applied Biosystems Inc.

Applied Biosystems Inc. (formerly known as Applera Corporation) is a global leader in the development and marketing of instrument-based systems, consumables, software, and services for academic research, the life science industry and commercial markets. Driven by its employees' belief in the power of science to improve the human condition, the company commercializes innovative technology solutions for DNA, RNA, protein and small molecule analysis. Customers across the disciplines of academic and clinical research, pharmaceutical research and manufacturing, forensic DNA analysis, and agricultural biotechnology use the company's tools and services to accelerate scientific discovery, improve processes related to drug discovery and development, detect potentially pathogenic microorganisms, and identify individuals based on DNA sources. Applied Biosystems has a comprehensive service and field applications support team for a global installed base of high-performance genetic and protein analysis solutions. Applied Biosystems Inc. is headquartered in Norwalk, CT. On June 12, 2008, Applera Corporation and Invitrogen Corporation (NASDAQ: IVGN) announced that their Boards of Directors had approved a definitive merger agreement under which Invitrogen will acquire all of the outstanding shares of Applied Biosystems stock. The merger is subject to customary closing conditions and is targeted to close in the fall of 2008. Further information regarding the merger will be provided in a joint proxy statement/prospectus to be mailed to stockholders of the company and Invitrogen. Investors and security holders are urged to read this document when it becomes available because it will contain important information. Information about Applied Biosystems, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.appliedbiosystems.com.